The manner in which the posterior pituitary hormones are carried in the plasma has not been clarified but seems to differ from one species to another1). Several evidences have been brought forward to indicate that vasopressin in human plasma is bound with the plasma protein2, 3, 4). Our previous observation showed different vasopressin binding capacity between the plasma samples obtained from different individuals (unpublished data). The present study was first aimed to reinvestigate the variation in the binding capacity using a larger number of freshly obtained human, dog and rat serum and plasma samples. During the course of the investigation on the vasopressin-serum protein binding we have noticed that the pressor activity of vasopressin added to human serum is usually lower than that of vasopressin in physiological saline in the same concentration as in the serum and that the reduction of the pressor activity by the serum varied in extent from one sample to another.
The fall of the pressor activity may probably be due to inactivation of the hormone by serum.
But it may also be possible that binding itself participates in reducing the activity5) or interferes the degradation of vasopressin in the serum. The paper presented here deals with in vitro study to attempt to clarify this problem.
MATERIALS AND METHODS
The specimens of human plasma were collected from the cubital vein of the adult subjects working in this laboratory or the blood donors at the Sapporo Blood Bank. The dog blood was obtained from the femoral artery without anesthesia and the rat blood collected from the abdominal aorta under ether anesthesia.
The serum separated was kept in a refrigerator until used. The pressor activity of the hormone was determined using Dibenzyline treated rats as described in the U. S. PHARMACOPEIA6), with the exception that the blood pressure of the femoral artery was measured and recorded by means of an electronic manometer (Nihon Koden). The standard and the unknown samples were injected at two dosage levels into the rat's femoral vein through a small polyethylene tube cannulated. Fractionation of the serum or plasma proteins was carried out using cold ethanol according to the method 6 of COHN7). Each fraction was dissolved in Ringer solution adjusting its pH to 7.4 with sodium bicarbonate solution and final volume was made up that of the serum or plasma from which the fraction was separated.
RESULTS
Reduction of the pressor activity of Pitressin by serum. Pitressin was mixed with human, dog or rat serum in a concentration of 20 mU per 1 ml and its pressor activity was compared with that of the Pitressin-saline solution of the same concentration.
When both the sample and the standard were assayed in a Dibenzyline treated rat without adjusting its pH the activity of the former was usually lower than the latter in most of the human sera studied.
However, the extent in reduction of the pressor activity by human serum differed from one sample to another (FIG. 1) . Some human sera did not influence the activity of the added hormone, but others reduced the activity to the half of the standard.
The activity of Pitressin added in 2 specimens of dog serum decreased in both cases. On the other hand all the rat serum samples studied did not affect the pressor activity at all (FIG. 1) .
The effect of acidification of the serum. When the Pitressin-serum mixture was acidified soon after the hormone was added to the serum, no reduction of the pressor activity resulted ( further inactivation of the hormone and it was injected into an assay rat to see if the fall in the activity progressed with time at the room temperature. Since the response of an assay animal to a given dose of Pitressin is not always constant throughout an experiment, the standard Pitressin-saline solution was injected alternatively or with every two test samples to compare the activity of the test samples with that of the standard.
Although this method In the pressor assay employed the test sample and the standard at 2 dosage levels were repeatedly injected into an assay rat at room temperature and one assay usually took 2 hours during which the activity of serum-Pitressin mixture might reduce.
When a serum-Pitressin mixture were stood for 1 hour at room temperature, then acidified and its activity was measured, the activity evaluated could be less than that of the standard by an extent equal to that lost during 1 hour period at room temperature.
As shown in TABLE 3, Difference between serum and plasma in their effects on the reduction of Pitressin activity and their Pitressin-binding capacities.
It is generally accepted that the biological activity of vasopressin is more quickly reduced by serum than plasma8). This was also found in the experimental condition used here. As shown in TABLE 4, pressor activity of Pitressin added to human plasma was same or rather larger than that of the Pitressin-saline solution of the same concentration.
On the other hand, the activity of the hormone mixed with human serum was much lower than that of the standard solution in 5 out of 7 samples tested. The same experiment with the rat serum indicated that Pitressin added was well bound with large molecules in the serum but not reduced in activity under the experimental condition used (FIG. 2) Cohn fractions of the human serum participating in the reduction of the pressor activity of Pitressin. A series of experiment was made in an attempt to see what fraction of the serum attributed to the reduction in the activity of Pitressin.
As shown in TABLE 5, fractions II+III & IV-4 played the most remarkable effect on it. The reduction of the pressor activity by COHN fraction IV-4 was larger in extent in some cases than that by the original serum from which the fraction was separated.
However, it was found that fraction IV-4 itself sometimes possessed a depressor activity probably due to depressor The fall of pressor activity of the hormone by fractions II+III or IV-4 did not occur if the pH of the sample was adjusted to 3 shortly after Pitressin was added to each fraction (TABLE 6). serum fraction. If the fraction itself possessed a depressor activity, the reduction of the activity of Pitressin by the fraction was corrected by simple addition of the blood pressure fell by injection of the fraction into the assay animal.
As shown in FIG. 3 
DISCUSSION
The findings reported here deals with the reduction of pressor activity of the neurohypophysial preparation and the binding of the active principles by serum and plasma in vitro.
Although it was hoped to employ arginine-vasopressin because of the natural hormone in human, dog and rat, inavailability of this preparation obliged us to substitute Pitressin throughout the experiment.
The active pressor substances tested in these experiments, therefore, included both arginine-and lysine-vasopressin.
It may also be possible that binding and reduction of the activity of the hormone by serum is affected by other inert substances than vasopressin contained in Pitressin. The concentration of the hormone used in this study was 20 mU/ml which was the smallest amount to be accurately assayed for its pressor activity in our hand. but it far exceeded the physiological concentration. Variation was seen not only in the binding capacity but also in the capacity of serum to reduce the pressor activity of Pitressin in vitro at room temperature.
HIPSLEY5) reported that bound Pitressin in human plasma could not elicit antidiuresis when it was injected into a hydrated rat and the antidiuretic activity was restored after boiling the plasma-Pitressin mixture.
He suggested that binding of the hormone by plasma protein diminished its biological activity. We also examined the possiblity that bound vasopressin was deprived of pressor activity.
If it is the case, the serum with larger binding capacity might reduce the pressor activity to larger extent.
Actually, a significant correlation was found between the binding and pressor-activity-reducing capacities of the added Pitressin by human serum.
Pressor activity was determined by an established assay method using a Dibenzyline treated rats, and it usually took 2 hours for each sample during which inactivation of the hormone by serum may take place. The activitymeasured by this assay method may be influenced by inactivation of the hormone progressing during the period of assay unless the inactivating process is blocked.
When the serum-Pitressin mixture was stood for 1 hour at room. temperature, then its pH adjusted to 3.0 and assayed, the value well coincided with that of the same sample assayed without acidification. Further, the pressor activity of Pitressin-serum mixture progressively fell with time when it was tested by injecting the sample alternatively with the standard salinePitressin solution into an assay rat. The reduced activity was not restored by splitting bound Pitressin by acidification.
Human plasma which was shown to bind Pitressin failed to reduce the pressor activity.
These findings indicate that reduction of pressor activity by serum is not due to binding of the hormone by serum protein, but mainly inactivation.
It is of interest to note a significant correlation between the capacity of human serum to inactivate Pitressin and that to bind the hormone. This correlationship was also seen in COHN fractions separated from human serum. Among the fractions examined, fraction and fraction IV-4 contributed to both binding and inactivation of the hormone.
Neither fraction IV-1 nor V participated in these reactions. Fraction I was also ruled out from possible role in both binding and inactivation of the hormone. 
